Advertisement

The Effect of Inhalant Organic Dust on Bone Health

  • Joseph M. Carrington
  • Jill A. Poole
Allergies and the Environment (M Hernandez, Section Editor)
  • 85 Downloads
Part of the following topical collections:
  1. Topical Collection on Allergies and the Environment

Abstract

Purpose of Review

Agriculture remains a major economic sector globally, and workers experience high rates of chronic inflammatory lung and musculoskeletal diseases. Whereas obstructive pulmonary diseases are known risk factors for bone loss, the underlying relationship between lung inflammation and bone health is not well known.

Recent Findings

An agriculture organic dust extract inhalation animal model has recently linked lung injury-induced inflammation to systemic bone loss. This process is dependent upon lipopolysaccharide and the toll-like receptor 4 (TLR4) signaling pathway. Downstream systemic interleukin-6 is a key mediator that subsequently activates osteoclastogenesis. Age is a host factor that impacted bone disease with younger mice demonstrating increased susceptibility to bone loss following inhalant exposures as compared to older mice. Supplemental dietary vitamin D was shown to prevent organic dust-induced bone loss, but not lung disease, in animals.

Summary

Recent animal studies provide new mechanistic insight into the lung-bone inflammatory axis. Host factors, diet, and lipopolysaccharide/TLR4 signaling pathways play a significant role in explaining how inhalant organic dust exposures impact bone health. These investigations might lead to specific targeted therapeutic approaches.

Keywords

Organic dust Bone Endotoxin COPD Interleukin (IL)-6 Toll-like receptor 4/TLR4 

Notes

Acknowledgements

The authors wish to thank Melissa Carrington for the graphical assistance with the figure design.

Funding Information

This study is supported by grants from the National Institute of Environmental Health Sciences (R01: ES019325 to JAP) and National Institute of Occupational Safety and Health (U54OH010162 to JAP). This work was supported in part by the Central States Center for Agricultural Safety and Health (CS-CASH).

Compliance with Ethical Standards

Conflict of Interest

Dr. Poole reports grants from NIH/NIEHS. Dr. Carrington declares no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: Of importance •• Of major importance

  1. 1.
    Von Essen S, Romberger D. The respiratory inflammatory response to the swine confinement building environment: the adaptation to respiratory exposures in the chronically exposed worker. J Agric Saf Health. 2003;9(3):185–96.  https://doi.org/10.13031/2013.13684.CrossRefGoogle Scholar
  2. 2.
    Eduard W, Pearce N, Douwes J. Chronic bronchitis, COPD, and the lung function in farmers: the role of biological agents. Chest. 2009;136(3):716–25.  https://doi.org/10.1378/chest.08-2192.CrossRefPubMedGoogle Scholar
  3. 3.
    Poole JA. Farming-associated environmental exposures and the effect on atopic diseases. Ann Allergy Asthma Immunol. 2012;109(2):93–8.  https://doi.org/10.1016/j.anai.2011.12.014.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Kirkhorn SR, Garry VF. Agricultural lung diseases. Environ Health Perspect. 2000;108(Suppl 4):705–12.  https://doi.org/10.1289/ehp.00108s4705.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    • Osborne A, Blake C, Fullen BM, Meredith D, Phelan J, McNamara J, et al. Prevalence of musculoskeletal disorders among farmers: a systematic review. Am J Ind Med. 2012;55:143–58.  https://doi.org/10.1002/ajim.21033. Complete review of the various musculoskeletal disorders found within a farming population. CrossRefPubMedGoogle Scholar
  6. 6.
    Osborne A, Blake C, Fullen BM, Meredith D, Phelan J, McNamara J, et al. Risk factors for musculoskeletal disorders among farm owners and farm workers: a systematic review. Am J Ind Med. 2012;55(4):376–89.  https://doi.org/10.1002/ajim.22001.CrossRefPubMedGoogle Scholar
  7. 7.
    Murphy D, Hutchinson D. Is male rheumatoid arthritis an occupational disease? A review. Open Rheumatol J. 2017;11(1):88–105.  https://doi.org/10.2174/1874312901711010088.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    •• Lehouck A, Boonen S, Decramer M, Janssens W. COPD, bone metabolism, and osteoporosis. Chest. 2011;139:648–57.  https://doi.org/10.1378/chest.10-1427. Comprehensive review article on COPD and bone loss disease associations. CrossRefPubMedGoogle Scholar
  9. 9.
    • Graat-Verboom L, Smeenk FW, van den Borne BE, Spruit MA, Donkers-van Rossum AB, Aarts RP, et al. Risk factors for osteoporosis in Caucasian patients with moderate chronic obstructive pulmonary disease: a case control study. Bone. 2012;50:1234–9.  https://doi.org/10.1016/j.bone.2012.02.638. Important and well-designed case control study demonstrating risk factors for osteoporosis in subjects with COPD. CrossRefPubMedGoogle Scholar
  10. 10.
    Robertson J, Macdonald K. Prevalence of bone loss in a population with cystic fibrosis. Br J Nurs. 2010;19(10):636–9.  https://doi.org/10.12968/bjon.2010.19.10.48202.CrossRefPubMedGoogle Scholar
  11. 11.
    Chauhan V, Ranganna KM, Chauhan N, Vaid M, Kelepouris E. Bone disease in organ transplant patients: pathogenesis and management. Postgrad Med. 2012;124(3):80–90.  https://doi.org/10.3810/pgm.2012.05.2551.CrossRefPubMedGoogle Scholar
  12. 12.
    •• Jung JW, Kang HR, Kim JY, Lee SH, Kim SS, Cho SH. Are asthmatic patients prone to bone loss? Ann Allergy Asthma Immunol. 2014;112:426–31.  https://doi.org/10.1016/j.anai.2014.02.013. Clinical research study demonstrating a positive relationship between airway hyper-responsiveness and asthma to bone mineral density loss that is independent of corticosteroid use. CrossRefPubMedGoogle Scholar
  13. 13.
    Holly EA, Aston DA, Ahn DK, Kristiansen JJ. Ewing’s bone sarcoma, paternal occupational exposure, and other factors. Am J Epidemiol. 1992;135(2):122–9.  https://doi.org/10.1093/oxfordjournals.aje.a116265.CrossRefPubMedGoogle Scholar
  14. 14.
    Moore LE, Gold L, Stewart PA, Gridley G, Prince JR, Zahm SH. Parental occupational exposures and Ewing’s sarcoma. Int J Cancer. 2005;114(3):472–8.  https://doi.org/10.1002/ijc.20734.CrossRefPubMedGoogle Scholar
  15. 15.
    Wilkins RM, Pritchard DJ, Omer EB, Unni KK. Ewing’s sarcoma of bone. Experience with 140 patients. Cancer. 1986;58(11):2551–5.  https://doi.org/10.1002/1097-0142(19861201)58:11<2551::AID-CNCR2820581132>3.0.CO;2-Y.CrossRefPubMedGoogle Scholar
  16. 16.
    Taylor R, Knowles HJ, Athanasou NA. Ewing sarcoma cells express RANKL and support osteoclastogenesis. J Pathol. 2001;225(2):195–202.CrossRefGoogle Scholar
  17. 17.
    Rucci N, Teti A. Osteoclasts: essentials and methods. In: Pietschmann P, editor. Principles of bone and joint research. Learning materials in biosciences. Cham: Springer; 2017.  https://doi.org/10.1007/978-3-319-58955-8_3.Google Scholar
  18. 18.
    Rucci N. Molecular biology of bone remodelling. Clin Cases Miner Bone Metab. 2008;5(1):49–56.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Poole JA, Romberger DJ. Immunological and inflammatory responses to organic dust in agriculture. Curr Opin Allergy Clin Immunol. 2012;12(2):126–32.  https://doi.org/10.1097/ACI.0b013e3283511d0e.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Ivanov S, Palmberg L, Venge P, Larsson K, Linden A. Interleukin-17A mRNA and protein expression within cells from the human bronchoalveolar space after exposure to organic dust. Respir Res. 2005;6:44.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Poole JA, Gleason AM, Bauer C, West WW, Alexis N, van Rooijen N, et al. CD11c+/CD11b+ cells are critical for organic dust-elicited murine lung inflammation. Am J Respir Cell Mol Biol. 2012;47(5):652–9.  https://doi.org/10.1165/rcmb.2012-0095OC.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Robbe P, Draijer C, Borg TR, Luinge M, Timens W, Wouters IM, et al. Distinct macrophage phenotypes in allergic and nonallergic lung inflammation. Am J Physiol Lung Cell Mol Physiol. 2015;308(4):L358–67.  https://doi.org/10.1152/ajplung.00341.2014.CrossRefPubMedGoogle Scholar
  23. 23.
    Poole JA, Gleason AM, Bauer C, West WW, Alexis N, Reynolds SJ, et al. Alphabeta T cells and a mixed Th1/Th17 response are important in organic dust-induced airway disease. Ann Allergy Asthma Immunol. 2012;109(4):266–273.e2.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    • Gao Z, Dosman JA, Rennie DC, Schwartz DA, Yang IV, Beach J, et al. Association of Toll-like receptor 2 gene polymorphisms with lung function in workers in swine operations. Ann Allergy Asthma Immunol. 2013;110(1):44–50.e1. First clinical research study to link genetic polymorphisms in toll-like receptor 2 to lung function in swine workers. CrossRefPubMedGoogle Scholar
  25. 25.
    Senthilselvan A, Chenard L, Kirychuk S, Predicala B, Schwartz DA, Burch LH, et al. Gender-related tumor necrosis factor-alpha responses in naive volunteers with toll-like receptor 4 polymorphisms exposed in a swine confinement facility. J Interf Cytokine Res. 2009 Dec;29(12):781–90.  https://doi.org/10.1089/jir.2009.0002.CrossRefGoogle Scholar
  26. 26.
    Sahlander K, Larsson K, Palmberg L. Daily exposure to dust alters innate immunity. PLoS One. 2012;7(2):e31646.  https://doi.org/10.1371/journal.pone.0031646.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Wells A, Romberger DJ, Thiele GM, Wyatt TA, Staab E, Heires AJ, et al. Systemic IL-6 effector response in mediating systemic bone loss following inhalation of organic dust. J Interf Cytokine Res Off J Int Soc Interf Cytokine Res. 2017;37(1):9–19.  https://doi.org/10.1089/jir.2016.0048.CrossRefGoogle Scholar
  28. 28.
    Bauer C, Kielian T, Wyatt TA, Romberger DJ, West WW, Gleason AM, et al. Myeloid differentiation factor 88-dependent signaling is critical for acute organic dust-induced airway inflammation in mice. Am J Respir Cell Mol Biol. 2013;48(6):781–9.  https://doi.org/10.1165/rcmb.2012-0479OC.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Poole JA, Wyatt TA, Oldenburg PJ, Elliott MK, West WW, Sisson JH, et al. Intranasal organic dust exposure-induced airway adaptation response marked by persistent lung inflammation and pathology in mice. Am J Physiol Lung Cell Mol Physiol. 2009;296(6):L1085–95.  https://doi.org/10.1152/ajplung.90622.2008.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Robbe P, Spierenburg EA, Draijer C, Brandsma CA, Telenga E, van Oosterhout AJ, et al. Shifted T-cell polarisation after agricultural dust exposure in mice and men. Thorax. 2014;69(7):630–7.  https://doi.org/10.1136/thoraxjnl-2013-204295.CrossRefPubMedGoogle Scholar
  31. 31.
    Poole JA, Mikuls TR, Duryee MJ, Warren KJ, Wyatt TA, Nelson AJ, et al. A role for B cells in organic dust induced lung inflammation. Respir Res. 2017;18(1):214.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Poole JA, Romberger DJ, Bauer C, Gleason AM, Sisson JH, Oldenburg PJ, et al. Protein kinase C epsilon is important in modulating organic-dust-induced airway inflammation. Exp Lung Res. 2012 Oct;38(8):383–95.  https://doi.org/10.3109/01902148.2012.714841.CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Knetter SM, Tuggle CK, Wannemuehler MJ, Ramer-Tait AE. Organic barn dust extract exposure impairs porcine macrophage function in vitro: implications for respiratory health. Vet Immunol Immunopathol. 2014 Jan 15;157(1–2):20–30.  https://doi.org/10.1016/j.vetimm.2013.10.019.CrossRefPubMedGoogle Scholar
  34. 34.
    Poole JA, Kielian T, Wyatt TA, Gleason AM, Stone J, Palm K, et al. Organic dust augments nucleotide-binding oligomerization domain expression via an NF-{kappa}B pathway to negatively regulate inflammatory responses. Am J Physiol Lung Cell Mol Physiol. 2011 Sep;301(3):L296–306.  https://doi.org/10.1152/ajplung.00086.2011.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Poole JA, Anderson L, Gleason AM, West WW, Romberger DJ, Wyatt TA. Pattern recognition scavenger receptor A/CD204 regulates airway inflammatory homeostasis following organic dust extract exposures. J Immunotoxicol. 2015;12(1):64–73.  https://doi.org/10.3109/1547691X.2014.882449.CrossRefPubMedGoogle Scholar
  36. 36.
    Boissy RJ, Romberger DJ, Roughead WA, Weissenburger-Moser L, Poole JA, LeVan TD. Shotgun pyrosequencing metagenomic analyses of dusts from swine confinement and grain facilities. PLoS One. 2014;9(4):e95578.  https://doi.org/10.1371/journal.pone.0095578.CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Poole JA, Dooley GP, Saito R, Burrell AM, Bailey KL, Romberger DJ, et al. Muramic acid, endotoxin, 3-hydroxy fatty acids, and ergosterol content explain monocyte and epithelial cell inflammatory responses to agricultural dusts. J Toxicol Environ Health A. 2010;73(10):684–700.  https://doi.org/10.1080/15287390903578539.CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    • Dusad A, Thiele GM, Klassen LW, Gleason AM, Bauer C, Mikuls TR, et al. Organic dust, lipopolysaccharide, and peptidoglycan inhalant exposures result in bone loss/disease. Am J Respir Cell Mol Biol. 2013;49(5):829–36. First animal study to demonstrate that repetitive environmental inflammatory agents causing lung inflammation result in bone mineral density loss. CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Krisher T, Bar-Shavit Z. Regulation of osteoclastogenesis by integrated signals from toll-like receptors. J Cell Biochem. 2014;115(12):2146–54.  https://doi.org/10.1002/jcb.24891.CrossRefPubMedGoogle Scholar
  40. 40.
    Poole JA, Wyatt TA, Kielian T, Oldenburg P, Gleason AM, Bauer A, et al. Toll-like receptor 2 regulates organic dust-induced airway inflammation. Am J Respir Cell Mol Biol. 2011;45(4):711–9.  https://doi.org/10.1165/rcmb.2010-0427OC.CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Charavaryamath C, Juneau V, Suri SS, Janardhan KS, Townsend H, Singh B. Role of toll-like receptor 4 in lung inflammation following exposure to swine barn air. Exp Lung Res. 2008;34(1):19–35.  https://doi.org/10.1080/01902140701807779.CrossRefPubMedGoogle Scholar
  42. 42.
    • Staab E, Thiele GM, Clarey D, Wyatt TA, Romberger DJ, Wells AD, et al. Toll-like receptor 4 signaling pathway mediates inhalant organic dust-induced bone loss. PloS One. 2016; 11(8):e0158735.  https://doi.org/10.1371/journal.pone.0158735. Animal study highlighting an important role for endotoxin and the toll-like receptor 4 signaling pathway in mediating bone loss consequences following complex agriculture organic dust exposures.
  43. 43.
    Ferrari R, Tanni SE, Caram LM, Correa C, Correa CR, Godoy I. Three-year follow-up of interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir Res. 2013;14(1):24.  https://doi.org/10.1186/1465-9921-14-24.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Sin DD, Macnee W. Chronic obstructive pulmonary disease and cardiovascular diseases: a “vulnerable” relationship. Am J Respir Crit Care Med. 2013;187(1):2–4.  https://doi.org/10.1164/rccm.201210-1953ED.CrossRefPubMedGoogle Scholar
  45. 45.
    •• Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. BioMed Res Int. 2014;  https://doi.org/10.1155/2014/698313. A comprehensive review article on the mechanistic role of IL-6 and bone disease.
  46. 46.
    Briot K, Rouanet S, Schaeverbeke T, Etchepare F, Gaudin P, Perdriger A, et al. The effect of tocilizumab on bone mineral density, serum levels of dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Joint Bone Spine. 2015;82(2):109–15.  https://doi.org/10.1016/j.jbspin.2014.10.015.CrossRefPubMedGoogle Scholar
  47. 47.
    Tanaka T, Narazaki M, Ogata A, Kishimoto T. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol. 2014;26(1):88–96.  https://doi.org/10.1016/j.smim.2014.01.009.CrossRefPubMedGoogle Scholar
  48. 48.
    Caramori G, Adcock IM, Di Stefano A, Chung KF. Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:397–412.  https://doi.org/10.2147/COPD.S42544.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Wedzicha JA, Seemungal TAR, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000;84(2):210–5.PubMedGoogle Scholar
  50. 50.
    Romberger DJ, Bodlak V, Von Essen SG, Mathisen T, Wyatt TA. Hog barn dust extract stimulates IL-8 and IL-6 release in human bronchial epithelial cells via PKC activation. J Appl Physiol. 2002;93(1):289–96.  https://doi.org/10.1152/japplphysiol.00815.2001.CrossRefPubMedGoogle Scholar
  51. 51.
    Poole JA, Romberger DJ, Wyatt TA, Staab E, VanDeGraaff J, Thiele GM, et al. Age impacts pulmonary inflammation and systemic bone response to inhaled organic dust exposure. J Toxicol Environ Health A. 2015;78(19):1201–16.  https://doi.org/10.1080/15287394.2015.1075165.CrossRefPubMedCentralPubMedGoogle Scholar
  52. 52.
    Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–42.  https://doi.org/10.1038/nature01658.CrossRefPubMedGoogle Scholar
  53. 53.
    • Sucur A, Katavic V, Kelava T, Jajic Z, Kovacic N, Grcevic D. Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis. Int Orthop. 2014;38(9):1893–903. Informative review article outlining the mechanisms of the role of osteoclast precursor cells induced by inflammatory conditions relating to bone health. CrossRefPubMedGoogle Scholar
  54. 54.
    Xiao Y, Song JY, de Vries TJ, Fatmawati C, Parreira DB, Langenbach GE, et al. Osteoclast precursors in murine bone marrow express CD27 and are impeded in osteoclast development by CD70 on activated immune cells. Proc Natl Acad Sci U S A. 2013;110(30):12385–90.  https://doi.org/10.1073/pnas.1216082110.CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Dusad A, Thiele GM, Klassen LW, Wang D, Duryee MJ, Mikuls TR, et al. Vitamin D supplementation protects against bone loss following inhalant organic dust and lipopolysaccharide exposures in mice. Immunol Res. 2015;62(1):46–59.  https://doi.org/10.1007/s12026-015-8634-4.CrossRefPubMedCentralPubMedGoogle Scholar
  56. 56.
    Wu Y, Lee JW, Uy L, Abosaleem B, Gunn H, Ma M, et al. Tartrate-resistant acid phosphatase (TRACP 5b): a biomarker of bone resorption rate in support of drug development: modification, validation and application of the BoneTRAP kit assay. J Pharm Biomed Anal. 2009;49(5):1203–12.  https://doi.org/10.1016/j.jpba.2009.03.002.CrossRefPubMedGoogle Scholar
  57. 57.
    Shirjang S, Mansoori B, Solali S, Hagh MF, Shamsasenjan K. Toll-like receptors as a key regulator of mesenchymal stem cell function: an up-to-date review. Cell Immunol. 2017;315:1–10.  https://doi.org/10.1016/j.cellimm.2016.12.005.CrossRefPubMedGoogle Scholar
  58. 58.
    Fletcher C, Peto R, Tinker CM, Speizer FE. The natural history of chronic bronchitis and emphysema. Oxford: Oxford University Press; 1976.Google Scholar
  59. 59.
    Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax. 2006;61(6):472–7.  https://doi.org/10.1136/thx.2005.052449.CrossRefPubMedCentralPubMedGoogle Scholar
  60. 60.
    Miller RD, Hepper NG, Kueppers F, Gordon H, Offord KP. Host factors in chronic obstructive pulmonary disease in an upper Midwest rural community. Design, case selection, and clinical characteristics in a matched-pair study. Mayo Clin Proc. 1976;51(11):709–15.PubMedGoogle Scholar
  61. 61.
    Elizondo-Montemayor L, Castillo EC, Rodríguez-López C, Villarreal-Calderón JR, Gómez-Carmona M, Tenorio-Martínez S, et al. Seasonal variation in vitamin D in association with age, inflammatory cytokines, anthropometric parameters, and lifestyle factors in older adults. Mediat Inflamm. 2017;2017:1–14.  https://doi.org/10.1155/2017/5719461.CrossRefGoogle Scholar
  62. 62.
    Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab. 1998;83(7):2239–43.  https://doi.org/10.1210/jcem.83.7.4708.PubMedGoogle Scholar
  63. 63.
    Knabe C, Mele A, Kann PH, Peleska B, Adel-Khattab D, Renz H, et al. Effect of sex-hormone levels, sex, body mass index and other host factors on human craniofacial bone regeneration with bioactive tricalcium phosphate grafts. Biomaterials. 2017;123:48–62.  https://doi.org/10.1016/j.biomaterials.2017.01.035.CrossRefPubMedGoogle Scholar
  64. 64.
    • Reed DB, Rayens MK, Conley CK, Westneat S, Adkins SM. Farm elders define health as the ability to work. Work Health Saf. 2017;60(8):345–51. Study that outlines the impact of specific health conditions in older farm workers in the ability to function. CrossRefGoogle Scholar
  65. 65.
    Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45.  https://doi.org/10.4065/83.9.1032.CrossRefPubMedCentralPubMedGoogle Scholar
  66. 66.
    Rizzoli R, Reginster J-Y, Boonen S, Bréart G, Diez-Perez A, Felsenberg D, et al. Adverse reactions and drug–drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011;89(2):91–104.  https://doi.org/10.1007/s00223-011-9499-8.CrossRefPubMedCentralPubMedGoogle Scholar
  67. 67.
    Josse R, Khan A, Ngui D, Shapiro M. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. Curr Med Res Opin. 2013;29(3):205–16.  https://doi.org/10.1185/03007995.2013.763779.CrossRefPubMedGoogle Scholar
  68. 68.
    Krakauer T. Nuclear factor-kappaB: fine-tuning a central integrator of diverse biologic stimuli. Int Rev Immunol. 2008;27(5):286–92.  https://doi.org/10.1080/08830180802317957.CrossRefPubMedGoogle Scholar
  69. 69.
    • Khosla S. Increasing options for the treatment of osteoporosis. N Engl J Med. 2009;361(8):818–20.  https://doi.org/10.1056/NEJMe0905480. A relevant and complete review of the newer options available for the treatment of osteoporosis. CrossRefPubMedCentralPubMedGoogle Scholar
  70. 70.
    Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010;55(19):2049–61.  https://doi.org/10.1016/j.jacc.2010.03.013.CrossRefPubMedGoogle Scholar
  71. 71.
    Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96.  https://doi.org/10.1136/ard.2008.105197.CrossRefPubMedGoogle Scholar
  72. 72.
    Genovese MC, McKay JD, Nasonov EL, Mysler EF, Da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968–80.  https://doi.org/10.1002/art.23940.CrossRefPubMedGoogle Scholar
  73. 73.
    Schaper F, Rose-John S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015;26(5):475–87.  https://doi.org/10.1016/j.cytogfr.2015.07.004.CrossRefPubMedGoogle Scholar
  74. 74.
    • Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015;34:75–82.  https://doi.org/10.1016/j.coi.2015.02.008. A review article focused on the novel approaches and advances of targeting the IL-6 signaling pathway to reduce disease. CrossRefPubMedGoogle Scholar
  75. 75.
    Xiao H, Bid HK, Chen X, Wu X, Wei J, Bian Y, et al. Repositioning bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy. PLoS One. 2017;12(7)  https://doi.org/10.1371/journal.pone.0180297.
  76. 76.
    Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121(9):3375–83.  https://doi.org/10.1172/JCI57158.CrossRefPubMedCentralPubMedGoogle Scholar
  77. 77.
    Harada S, Mizoguchi T, Kobayashi Y, Nakamichi Y, Takeda S, Sakai S, et al. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res. 2012;27(2):461–73.  https://doi.org/10.1002/jbmr.555.CrossRefPubMedGoogle Scholar
  78. 78.
    Baldock PA, Thomas GP, Hodge JM, Baker SU, Dressel U, O’Loughlin PD, et al. Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. J Bone Miner Res. 2006;21(10):1618–26.  https://doi.org/10.1359/jbmr.060714.CrossRefPubMedGoogle Scholar
  79. 79.
    Takasu H, Sugita A, Uchiyama Y, Katagiri N, Okazaki M, Ogata E, et al. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest. 2006;116(2):528–35.  https://doi.org/10.1172/JCI24742.CrossRefPubMedCentralPubMedGoogle Scholar
  80. 80.
    Sakai S, Takaishi H, Matsuzaki K, Kaneko H, Furukawa M, Miyauchi Y, et al. 1-alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J Bone Miner Metab. 2009;27(6):643–52.  https://doi.org/10.1007/s00774-009-0084-4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pulmonary, Critical Care, Sleep and Allergy Division, Department of MedicineUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations